Drug intelligence / Profile preview

Jingning Granules

Development stage: Preclinical
Lead developer: Kangrentang
Modality: Small Molecules
Administration: Oral

Overview

Jingning Granules (静宁颗粒) is a traditional Chinese medicine (TCM) formulation developed for the treatment of pediatric attention deficit hyperactivity disorder (ADHD). It is used as an adjunct to cognitive training and aims to provide clinical benefit in managing symptoms of ADHD in children. The granule formulation is based on TCM principles, but the precise herbal composition and mechanism of action are not fully detailed in public sources. Preclinical studies have also explored related formulations for effects on neuroendocrine function and neurotransmitter modulation, suggesting possible central nervous system activity[1][4].

Brand names: Jingning Granules
Other names: 静宁颗粒

Targets

DRD2 (Dopamine D2 Receptor)DRD1 (Dopamine D1 Receptor)

Beyond the preview

Go deeper on Jingning Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jingning Granules.

Explore the full profile